Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20477235 | 1.00 | RNASEH1 (0.41) | RNASEH1L3MBTL1CYP1A2SMN1; SMN2RXFP1 | |
| SCHEMBL20477331 | 0.82 | ADCY10 (0.38) | RNASEH1L3MBTL1RXFP1NPSR1PLA2G2A | |
| SCHEMBL20477334 | 0.82 | ADCY10 (0.38) | RNASEH1L3MBTL1RXFP1NPSR1PLA2G2A | |
| SCHEMBL20477383 | 0.82 | CDC25A (0.42) | NPSR1PLA2G2ADRD2TBXA2RCNR2 | |
| SCHEMBL20477386 | 0.82 | CDC25A (0.42) | NPSR1PLA2G2ADRD2TBXA2RCNR2 | |
| SCHEMBL9280321 | 0.77 | RNASEH1 (0.48) | RNASEH1L3MBTL1CYP1A2SMN1; SMN2RXFP1 | |
| SCHEMBL20477374 | 0.76 | RNASEH1 (0.47) | RNASEH1L3MBTL1CYP1A2SMN1; SMN2RXFP1 | |
| SCHEMBL20477364 | 0.74 | RNASEH1 (0.44) | RNASEH1L3MBTL1CYP1A2SMN1; SMN2RXFP1 | |
| SCHEMBL22079307 | 0.74 | RNASEH1 (0.57) | RNASEH1L3MBTL1CYP1A2SMN1; SMN2RXFP1 | |
| SCHEMBL28529853 | 0.73 | PDE5A (0.44) | L3MBTL1SMN1; SMN2NPSR1TBXA2RCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108431004-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| US-10787462-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3366684-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-20180319819-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-08 | — | — | US | disclosed |
| EP-3366684-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787462-B2 | Heterocyclic compound | RIPK1, RIPK4, RIPK3 | RNASEH1 1143/4885L3MBTL1 1421/4885CYP1A2 3702/4885 |
| US-20180319819-A1 | HETEROCYCLIC COMPOUND | RIPK1, RIPK4, RIPK3 | RNASEH1 1143/4885L3MBTL1 1421/4885CYP1A2 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.